KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cash & Current Investments (2016 - 2025)

Acadia Pharmaceuticals has reported Cash & Current Investments over the past 16 years, most recently at $819.7 million for Q4 2025.

  • Quarterly results put Cash & Current Investments at $819.7 million for Q4 2025, up 8.43% from a year ago — trailing twelve months through Dec 2025 was $819.7 million (up 8.43% YoY), and the annual figure for FY2025 was $819.7 million, up 8.43%.
  • Cash & Current Investments for Q4 2025 was $819.7 million at Acadia Pharmaceuticals, down from $847.0 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for ACAD hit a ceiling of $847.0 million in Q3 2025 and a floor of $345.9 million in Q3 2023.
  • Median Cash & Current Investments over the past 5 years was $510.8 million (2021), compared with a mean of $544.9 million.
  • Biggest five-year swings in Cash & Current Investments: decreased 22.81% in 2022 and later skyrocketed 72.26% in 2024.
  • Acadia Pharmaceuticals' Cash & Current Investments stood at $520.7 million in 2021, then decreased by 19.95% to $416.8 million in 2022, then grew by 5.29% to $438.9 million in 2023, then skyrocketed by 72.26% to $756.0 million in 2024, then grew by 8.43% to $819.7 million in 2025.
  • The last three reported values for Cash & Current Investments were $819.7 million (Q4 2025), $847.0 million (Q3 2025), and $762.0 million (Q2 2025) per Business Quant data.